Physician profile
Deandre M Carr
NPI 1568742146
$9,491.48
in general payments reported to CMS, 2019-2025
19 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $1,315 · 2021: $3,139 · 2022: $398 · 2023: $1,575 · 2024: $823 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,629 · Consulting Fee: $950 · Entertainment: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,629.19 |
| Consulting Fee | $950.00 |
| Entertainment | $102.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,548.22 | 2019-2025 | Total30, Precision 1, Dailies Total1 |
| Johnson & Johnson Vision Care, INC. | $935.28 | 2019-2025 | Acuvue |
| Coopervision INC. | $501.37 | 2022-2025 | Biofinity Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Glaukos Corporation | $370.47 | 2021-2025 | Ce-Marked Kxla System, Photrexa Viscous and Photrexa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $248.59 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $237.36 | 2024 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $229.69 | 2019-2021 | |
| Abbvie INC. | $218.71 | 2022-2025 | |
| Optos, INC. | $195.97 | 2020-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Ocular Therapeutix, INC. | $150.00 | 2025 | |
| Sun Pharmaceutical Industries INC. | $123.12 | 2020 | |
| Shire North American Group INC | $121.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $107.92 | 2022 | |
| Heidelberg Engineering, INC. | $105.63 | 2021 | |
| Astellas Pharma Global Development | $93.58 | 2024 | Izervay |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $90.67 | 2025 | Tecnis Simplicity |
| Integra Lifesciences Corporation | $84.20 | 2022 | |
| Allergan, INC. | $81.16 | 2019 | |
| Derma Sciences, INC. | $48.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deandre Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.